NNI-351 – (929607-23-8)

NNI-351 is an investigational oral drug developed by NeuroNascent, Inc., designed to enhance neurogenesis by inhibiting DYRK1A. It is currently in preclinical development for the treatment of Down syndrome, depression, and post-traumatic stress disorder (PTSD).

The drug’s mechanism of action involves promoting the proliferation of neuronal progenitors in the hippocampus, which is linked to reduced anxiety, improved learning, and decreased hyperactivity in animal models. For Down syndrome, NNI-351 has shown potential in reversing cognitive deficits in mouse models by promoting new neuron growth in the hippocampus.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/NNI-351
https://pubchem.ncbi.nlm.nih.gov/compound/16661882
https://www.medkoo.com/products/59191
https://neuronascent.com/rd-programs/developmental-delay/